Sonoma Pharmaceuticals, Inc.
SNOA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.05 | 0.00 | -0.16 |
| FCF Yield | -10.10% | -45.35% | -5.22% | 14.30% |
| EV / EBITDA | -5.59 | -1.65 | 3.76 | 1.18 |
| Quality | ||||
| ROIC | -2.54% | -10.96% | -9.76% | -10.35% |
| Gross Margin | 37.83% | 36.46% | 40.70% | 35.63% |
| Cash Conversion Ratio | 0.12 | 1.62 | -0.61 | -0.58 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.81% | 5.45% | 2.49% | 3.63% |
| Free Cash Flow Growth | 69.59% | -1,393.66% | -125.22% | 71.65% |
| Safety | ||||
| Net Debt / EBITDA | 3.60 | 2.77 | 8.11 | 5.13 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.96 | 0.67 | 0.76 | 0.73 |
| Cash Conversion Cycle | 101.02 | 120.28 | 169.54 | 129.31 |